IMA203CD8

IMA203 T cells are infused after lymphodepletion with fludarabine, and cyclophosphamide followed by low-dose IL-2. In summary, IMA203 shows a manageable safety profile and, to our knowledge, is the first TCR-T product candidate associated with frequent objective responses across multiple solid tumors at doses below 1 billion transduced T cells. Three expansion cohorts are currently being initiated to further study the safety and anti-tumor activity of IMA203 in solid tumors: IMA203 monotherapy at target dose, combination with a checkpoint inhibitor and a next-gen product candidate IMA203CD8 utilizing IMA203 co-transduced with a CD8 co-receptor.

Here, we show preclinical data from our next-generation product candidate IMA203CD8 utilizing the IMA203 TCR co-transduced with a CD8 co-receptor. The differential functional profiles of TCR-T cells co-expressing different types of CD8 constructs suggests that optimizing the type of co-receptor is relevant to maximize anti-tumor response and reveals CD8αβ to be the optimal co-receptor for the IMA203 PRAME TCR. Harnessing the anti-tumor potency of CD4 T cells may enhance depth and durability of anti-tumor responses and potentially improve the clinical outcome of TCR-T in patients with solid cancer.